4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Antiandrogen withdrawal syndrome with nilutamide.

      Biology

      Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, blood, drug therapy, secondary, Humans, Imidazoles, Imidazolidines, Male, Prostate-Specific Antigen, Prostatic Neoplasms, pathology, Substance Withdrawal Syndrome

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Antiandrogens are combined with medical or surgical castration to achieve total androgen blockade in metastatic prostate cancer. Discontinuation of antiandrogens at disease progression has been associated with prostate-specific antigen (PSA) decrease, symptom improvement, and occasionally objective tumor regression. Two cases of metastatic prostate cancer demonstrating decrease in PSA of 92% and 56% on discontinuation of nilutamide therapy are reported. Improvement in urinary symptoms, bone pain and, in one, disappearance of para-aortic lymphadenopathy paralleled the PSA decrease. The duration of the withdrawal response of 6 months was comparable to those reported with discontinuation of flutamide.

          Related collections

          Author and article information

          Journal
          9111642

          Comments

          Comment on this article